TGFB1 and cholangiocarcinoma: According to results from CCA versus non-CCA groups, we found that the integrated and combined analyses of novel candidate-biomarkers (TGF-β1, CA19-9, angiopoietin-2, and MUC5AC) tends to be a successful method for increasing the CCA diagnostic with adequate 82% sensitivity and 92% specificity.